| Patents for A61P 5 - Drugs for disorders of the endocrine system (28,908) |
|---|
| 05/10/2002 | WO2002036151A2 Use of the long pentraxin ptx3 for the preparation of medicament for the prevention and cure of autoimmune pathologies |
| 05/10/2002 | WO2002036105A2 Use of cortisol-sequestering agents for the treatment of hypercortisolaemia related disorders |
| 05/10/2002 | WO2001068697A3 Methods and compositions for immunoregulation |
| 05/10/2002 | WO2001064236A3 METHODS FOR TREATING FSH RELATED CONDITIONS WITH GnRH ANTAGONISTS |
| 05/10/2002 | WO2001034117A9 A method for chemoprevention of prostate cancer |
| 05/10/2002 | WO2001023389A3 Certain alkylene diamine-substituted heterocycles |
| 05/10/2002 | WO2000073507A3 Identification of a novel retrovirus associated with primary biliary cirrhosis and autoimmune disorders |
| 05/10/2002 | WO2000058339A3 50 human secreted proteins |
| 05/10/2002 | WO2000050639A3 Gene sequence variations with utility in determining the treatment of disease |
| 05/10/2002 | CA2427533A1 Use of the long pentraxin ptx3 for the preparation of medicament for the prevention and cure of autoimmune pathologies |
| 05/10/2002 | CA2427518A1 Polynucleotide encoding an activated human t-lymphocyte-derived protein related to ubiquitin conjugating enzyme |
| 05/09/2002 | US20020056146 Expression vector for use in generation of trangenic animals; for use in animal modeling of disease |
| 05/09/2002 | US20020055508 Benzofurazan compounds which enhance AMPA receptor activity |
| 05/09/2002 | US20020055142 Major intrinsic protein (MIP)-like polynucleotides, polypeptides, and antibodies |
| 05/09/2002 | US20020054902 Liposomes containing therapeutic genes are conjugated to targeting agents to provide transport of encapsulated gene across blood-retainal barrier and plasma membrane of ocular cell, where this gene expresses encoded therapeutical agent |
| 05/08/2002 | EP1203011A1 Orally active androgens |
| 05/08/2002 | EP1202989A1 Benzamide derivatives |
| 05/08/2002 | EP1202988A2 Novel integrin receptor antagonists |
| 05/08/2002 | EP1202980A1 2-arylimino-2,3-dihydrothiazoles, and their use thereof as somatostatin receptor ligands |
| 05/08/2002 | EP1202966A1 Piperidine alcohols |
| 05/08/2002 | EP1202738A1 Dihydropyrazine derivatives as npy antagonists |
| 05/08/2002 | EP1202731A2 Method for treating chronic pain using mek inhibitors |
| 05/08/2002 | EP1202726A2 Method for treating chronic pain using mek inhibitors |
| 05/08/2002 | CN1348462A Novel LHRH-antagonists with improved solubility characteristics |
| 05/08/2002 | CN1348461A 17 beta-acyl-17 alpha-propynyl-11 beta-arylsteroids and their derivatives having agonist or antagonist hormonal properties |
| 05/08/2002 | CN1348383A Prolonged release microsphere encapsulating luteinizing hormone-releasing hormone analogues and method for preparing the same |
| 05/08/2002 | CN1348370A Cyclic protein tyrosine kinase inhibitors |
| 05/08/2002 | CN1348363A Novel pharmaceutical salt form |
| 05/07/2002 | US6384221 Recrystallization purification |
| 05/07/2002 | US6384062 Pharmaceutical composition |
| 05/07/2002 | US6384041 Bicyclic sPLA2 inhibitors |
| 05/02/2002 | WO2002035235A2 Net as regulator of angiogenic expression |
| 05/02/2002 | WO2002034783A2 Transmembrane proteins |
| 05/02/2002 | WO2002034747A1 Novel 7-azaindoles, use thereof as phosphodiesterase 4 inhibitors and method for producing the same |
| 05/02/2002 | WO2002034721A1 Acylsemicarbazides and their use as cyclin dependent kinase (cdk) inhibitors |
| 05/02/2002 | WO2002034286A1 Methods for treating endocrine disorders |
| 05/02/2002 | WO2002034253A1 Hair growth stimulant |
| 05/02/2002 | WO2002034204A2 Calcilytic compounds |
| 05/02/2002 | WO2002034200A2 Transdermal therapeutic systems comprising photosensitive active substances |
| 05/02/2002 | WO2001091803A3 Methods and compounds for controlled release of recombinant parvovirus vectors |
| 05/02/2002 | WO2001087316A3 Composition and method for increasing testosterone levels |
| 05/02/2002 | WO2001077137A9 Albumin fusion proteins |
| 05/02/2002 | WO2001074840A3 17-alpha-substituted-11-beta-substituted-4-aryl and 21-substituted 19-norpregna 21-substituted 19-norpregnadienedione as antiprogestational agents |
| 05/02/2002 | WO2001072778A3 Method of identifying inhibitors of tie-2 |
| 05/02/2002 | WO2001062923A3 Transporters and ion channels |
| 05/02/2002 | WO2001062269A3 Use of neurotoxins for treating parathyroid disorders |
| 05/02/2002 | WO2001062266A3 Use of dpp-iv inhibitors for the treatment of diabetes |
| 05/02/2002 | WO2001061008A3 Polypeptides and nucleic acids encoding same |
| 05/02/2002 | WO2001058919A3 Synthesis of anti-estrogenic and other therapeutic steroids from 21-hydroxy-19-norpregna-4-en-3-one |
| 05/02/2002 | WO2001052829A3 Statin-type bone growth stimulators |
| 05/02/2002 | WO2001035949A3 Treatment or systemic lupus erythematosus (sle) with dehydroepiandrosterone |
| 05/02/2002 | WO2001034767A3 22 human secreted proteins |
| 05/02/2002 | WO2001029070A3 Modulation of t cell differentiation for the treatment of t helper cell mediated diseases |
| 05/02/2002 | WO2001018172A3 Fibroblast growth factor-like polypeptides |
| 05/02/2002 | WO2001009121A3 2-pyrazolin-5-ones_as tyrosine kinase inhibitors |
| 05/02/2002 | WO2000078972A3 Regulation with binding cassette transporter protein abc1 |
| 05/02/2002 | US20020052471 Human procalcitonin and the preparation and use thereof |
| 05/02/2002 | US20020052387 5-Substituted 2-aryl-4-pyrimidinones |
| 05/02/2002 | US20020052362 CRF receptor antagonists; treatment of endocrine, psychiatric and neurologic conditions or illnesses, including stress-related disorders |
| 05/02/2002 | US20020052326 Treating diabetes and related diseases in combination with one, two or more other antidiabetic agents and/or one, two or more hypolipidemic agents. |
| 05/02/2002 | US20020051822 Enhancing bone formation, inhibiting osteoclastic differentiation or activating osteoblastic differentialation by administering to a human or animal suffering from, or susceptible to bone disease a lanthanum compound |
| 05/02/2002 | EP1202065A1 Net, a transcription factor of the TCF family, as regulator of angiogenic expression. |
| 05/02/2002 | EP1201655A2 Process for the preparation of non-steroidal glucocorticoid receptor modulators |
| 05/02/2002 | EP1201649A1 Glucocorticoid receptor modulators |
| 05/02/2002 | EP1200596A2 Human synthetases |
| 05/02/2002 | EP1200595A2 Myxoma virus genes for immune modulation |
| 05/02/2002 | EP1200589A1 Modified ciliary neurotrophic factor, method of making and methods of use thereof |
| 05/02/2002 | EP1200587A2 Receptors and associated proteins |
| 05/02/2002 | EP1200586A2 Human nervous system-associated proteins |
| 05/02/2002 | EP1200582A2 Human proteins having hydrophobic domains and dnas encoding these proteins |
| 05/02/2002 | EP1200432A1 Amido spiropiperidines promote the release of growth hormone |
| 05/02/2002 | EP1200422A2 Pyrazole compositions useful as inhibitors of erk |
| 05/02/2002 | EP1200419A1 Aminothiazole derivatives and their use as crf receptor ligands |
| 05/02/2002 | EP1200399A1 Vitamin d3 analogs |
| 05/02/2002 | EP1200119A2 Method for down-regulating gdf-8 activity |
| 05/02/2002 | EP1200111A1 Compositions for the treatment of the catabolic state of prolonged critical illness |
| 05/02/2002 | EP1200076A1 Calcilytic compounds |
| 05/02/2002 | EP0841907B1 Use of agonists or antagonists of p2 purinoceptors for the prevention of glutamate-evoked cytotoxicity |
| 05/02/2002 | EP0615448B1 Sex steroid activity inhibitors |
| 05/02/2002 | CA2427085A1 Transmembrane proteins |
| 05/02/2002 | CA2420164A1 Acylsemicarbazides and their use as cyclin dependent kinase (cdk) inhibitors |
| 05/02/2002 | CA2325751A1 Fermented herbal drink |
| 05/01/2002 | CN1347420A Growth hormone secretagogues |
| 05/01/2002 | CN1347327A Methods for glucagon suppression |
| 05/01/2002 | CN1083830C Substd. benzamidines, their production and their use as medicaments |
| 04/30/2002 | US6380398 Compounds such as (s,s)1-(2-amino-3,3-dimethyl-butyryl)-2,5-dihydro-1h-pyrrole-2 -carbonitrile administered as antidiabetic agents; dipeptidyl peptidase-iv (dpp-iv) |
| 04/30/2002 | US6380355 Process for obtaining insulin precursors having correctly bonded cystine bridges |
| 04/30/2002 | US6380255 Treatment for dermal skin atrophy using thyroid hormone compounds or thyroid hormone-like compounds |
| 04/30/2002 | US6380235 Useful as progesterone receptor agonists and antagonists, used for contraception, in therapy of fibroids, endometriosis, breast, uterine, ovarian and prostate cancer, and post menopausal hormone replacement therapy |
| 04/30/2002 | US6380184 For increased production of wool, milk, and meat by treating animals with therapeutically effective amount of compound |
| 04/30/2002 | US6380179 Administering n-(1-methyl-1-(4-methoxyphenyl)ethyl)-3-oxo-4-aza-5alpha-andro st-1-ene-17beta-carbaxamide |
| 04/30/2002 | US6379927 Retinoblastoma fusion proteins |
| 04/25/2002 | WO2002033099A2 Human kinases |
| 04/25/2002 | WO2002033049A1 Human tuberoinfundibular peptide of 39 residues |
| 04/25/2002 | WO2002032961A2 Novel polypeptides and nucleic acids encoding same |
| 04/25/2002 | WO2002032955A1 Human gene critical to fertility |
| 04/25/2002 | WO2002032900A2 Aryl or heteroaryl fused imidazole compounds as anti-inflammatory and analgesic agents |
| 04/25/2002 | WO2002032893A2 Piperidine compounds as anti-allergic |
| 04/25/2002 | WO2002032888A1 Substituted dipeptides as growth hormone secretagogues |
| 04/25/2002 | WO2002032864A1 Pharmaceutically active sulfanilide derivatives |